Biblio
“Aging-Related Protein Alterations in the Brain.”, J Alzheimers Dis, vol. 99, no. s1, pp. S5-S22, 2024.
, “Alpha-, Beta-, and Gamma-Secretase, Amyloid Precursor Protein, and Tau Protein Genes in the Hippocampal CA3 Subfield in an Ischemic Model of Alzheimer's Disease with Survival up to 2 Years.”, J Alzheimers Dis, vol. 98, no. 1, pp. 151-161, 2024.
, “Amyloid-β Pathology Is the Common Nominator Proteinopathy of the Primate Brain Aging.”, J Alzheimers Dis, vol. 100, no. s1, pp. S153-S164, 2024.
, “Aniracetam: An Evidence-Based Model for Preventing the Accumulation of Amyloid-β Plaques in Alzheimer's Disease.”, J Alzheimers Dis, vol. 98, no. 4, pp. 1235-1241, 2024.
, “The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.”, J Alzheimers Dis, vol. 98, no. 1, pp. 13-32, 2024.
, “Blood Pressure Variability and Plasma Alzheimer's Disease Biomarkers in the SPRINT Trial.”, J Alzheimers Dis, vol. 97, no. 4, pp. 1851-1860, 2024.
, “A Continuous Extension of Gene Set Enrichment Analysis Using the Likelihood Ratio Test Statistics Identifies Vascular Endothelial Growth Factor as a Candidate Pathway for Alzheimer's Disease via ITGA5.”, J Alzheimers Dis, vol. 97, no. 2, pp. 635-648, 2024.
, “Interaction Between Arteriosclerosis and Amyloid-β on Cognitive Function.”, J Alzheimers Dis, vol. 97, no. 2, pp. 953-961, 2024.
, “Regional differences in glucose metabolic decline and tau deposition in the Alzheimer's continuum brain.”, J Alzheimers Dis, vol. 102, no. 1, pp. 228-236, 2024.
, “Senescence Targeting Methods Impact Alzheimer's Disease Features in 3xTg Mice.”, J Alzheimers Dis, vol. 97, no. 4, pp. 1751-1763, 2024.
, “Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons.”, J Alzheimers Dis, vol. 98, no. 2, pp. 643-657, 2024.
, “Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.”, J Alzheimers Dis, vol. 101, no. s1, pp. S129-S140, 2024.
, “Voluntary wheel running decreases amyloidogenic pathway and rescues cognition and mitochondrial energy metabolism in middle-aged female 3xTg-AD mouse model of Alzheimer's disease.”, J Alzheimers Dis, vol. 102, no. 2, pp. 424-436, 2024.
, “Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development.”, J Alzheimers Dis, vol. 91, no. 1, pp. 43-70, 2023.
, “Associations of the Harvard Automated Phone Task and Alzheimer's Disease Pathology in Cognitively Normal Older Adults: Preliminary Findings.”, J Alzheimers Dis, vol. 94, no. 1, pp. 217-226, 2023.
, “Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum.”, J Alzheimers Dis, vol. 92, no. 4, pp. 1385-1397, 2023.
, “Insights into the Pathophysiology of Alzheimer's Disease and Potential Therapeutic Targets: A Current Perspective.”, J Alzheimers Dis, vol. 91, no. 2, pp. 507-530, 2023.
, “Lithium Provides Broad Therapeutic Benefits in an Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 91, no. 1, pp. 273-290, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
, “Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance.”, J Alzheimers Dis, vol. 90, no. 3, pp. 967-974, 2022.
, “The Correlation of Tau Levels with Blood Monocyte Count in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1321-1328, 2022.
, “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
, “Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 503-518, 2022.
, “Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis.”, J Alzheimers Dis, vol. 79, no. 1, pp. 177-195, 2021.
,